BioSpace News Archive

It isn’t often that a contestant pulls ahead in a major contest and their competitor wins too, but Moderna – along with other COVID-19 vaccine contenders – will take it.

Oxford Immunotec Global PLC, a global, high-growth diagnostics company, announced the release of data from a prospective cohort study in keyworkers in the UK – a collaboration between the Company and Public Health England.

Global health service company Cigna Corporation (NYSE:CI) announced today that Tim Wentworth, Chief Executive Officer of Evernorth, will present at the Wolfe Research Healthcare Conference on November 19, 2020 through a virtual webcast.

Findings from a randomized controlled trial recently published in the Journal of the American College of Cardiology, indicate that people in their 60s and 70s who regularly consume walnuts may have reduced inflammation, a factor associated with a lower risk of heart disease, compared to those who do not eat walnuts.

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new immunotherapy data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, taking place November 9-14, 2020.

Four clinical studies found significant benefits for lung health when Prolacta Bioscience® 100% human milk-based nutritional fortifiers were used to nourish extremely preterm infants in the neonatal intensive care unit (NICU).

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a research collaboration with Thomas Jefferson University and the Sidney Kimmel Cancer Center – Jefferson Health for a study from the window of opportunity trial of Nivolumab and Tadalafil for patients with squamous cell carcinoma of the head and neck.

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross proceeds of $30 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TherapeuticsMD.

Silverback Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer and other serious diseases, today announced the appointment of Jonathan Piaz

American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T , a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated white blood cells, which will be used for manufacturing the AGT103-T cell product. After manufacturing and required safety testing, the product will be infused back into the tr